Piper Jaffray Upgrades Allscripts To Overweight, $22 PT

Piper Jaffray has upgraded Allscripts MDRX from Neutral to Overweight and has established a $22 price target.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: UpgradesPrice TargetAnalyst RatingsHealth CareHealth Care TechnologyPiper Jaffray
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!